Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
Michelle Hemkens, Katie Stamp, Lise I. Loberg, Kévin Moreau, T K Hart
Topics & Concepts
ADMEDrug developmentPharmacologyMedicineComputer scienceRisk analysis (engineering)DrugComputational biologyBiologyProtein Degradation and InhibitorsCAR-T cell therapy researchUbiquitin and proteasome pathways